Local neurotoxicity of Cisplatin after intra-arterial chemotherapy

Pomes, A.; Frustaci, S.; Cattaino, G; Grandis, D. De; Bongiovanni, L. G.; Tumolo, Salvatore; Quadu, G

doi:10.1111/j.1600-0404.1986.tb03281.x

Cited by 11 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Voice change, hoarseness, and vocal fold palsy are well-documented side effects of several chemotherapy agents including vinca alkaloids [ 24 ] and cisplatin [ 25 ]. Recently, voice change has been observed in patients receiving chemotherapy treatment protocols that include VEGF/R inhibitor drugs [ 17 , 18 , 26 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice

Damrose

2023

Case Reports in Otolaryngology

View full text Add to dashboard Cite

Background. Vascular endothelial growth factor/receptor (VEGF/R) inhibitors are used in chemotherapy protocols to limit tumor angiogenesis. Recent evidence shows they are associated with hoarseness, but their impact on vocal cord function has not been fully identified. Objectives. To describe the preliminary laryngeal findings in patients undergoing chemotherapy with VEGF/R inhibitors, and to describe possible mechanisms of their effect on vocal fold function. Methods. A retrospective case series was conducted in a tertiary medical center between July 2008 and August 2022. Cancer patients developing hoarseness while undergoing chemotherapy with VEGF/R inhibitors underwent videolaryngostroboscopy. Results. The study included four patients. There were three females and one male, treated for breast, lung, and unknown primary cancer, respectively. All 4 patients developed hoarseness 2–7 days after initiating treatment with the VEGF/R inhibitor drugs aflibercept (n = 1) and bevacizumab (n = 3). In all patients, videolaryngostroboscopy revealed vocal fold bowing and pronounced glottic insufficiency. There were no signs of mucositis or paralysis. In three patients, treatment involved speech therapy, with or without vocal fold augmentation. The average follow-up was 10 months (range 8–12 months). In 2 patients, there was a return of normal voice quality with resolution of vocal fold bowing. In one patient, who remained on chemotherapy, there was persistent bowing. Conclusions. VEGF/R inhibitors are associated with vocal fold bowing and glottic insufficiency. This appears to be a reversible side effect. To our knowledge, this is only the second clinical description of the effect of VEGF/R inhibitors on vocal fold function.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The VEGF/R inhibitor drugs in this series were given in combination with other chemotherapy agents, which may cause voice change themselves [ 25 ]. However, we have not previously encountered the specific finding of vocal fold bowing in patients receiving chemotherapy protocols that did not include VEGF/R inhibitors.…”

Section: Discussionmentioning

confidence: 99%

The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice

Damrose

2023

Case Reports in Otolaryngology

View full text Add to dashboard Cite

show abstract

“…Cranial nerve impairment was observed in patients who received intra-arterial cisplatin (Pomes et al, 1986), and intracarotid administration of cisplatin for CNS tumors may lead to serious optic toxicity (Shimamura et al, 1990;Maiese et al, 1992). Lumbosacral plexopathies were observed after intra-arterial cisplatin administration in the external or internal iliac arteries (Castellanos et al, 1987).…”

Section: Neuropathic Syndromementioning

confidence: 99%

Neurological complications of chemotherapy to the peripheral nervous system

Postma

Heimans

2012

Handbook of Clinical Neurology

View full text Add to dashboard Cite

Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer

Urba

Forastiere

1988

Cancer

View full text Add to dashboard Cite

A case of retrobulbar neuritis which developed in association with intraarterial continuous infusion cisplatin is presented. A 67-year-old man with squamous cell carcinoma of the left tonsillar fossa was treated with induction chemotherapy through the left lingual artery; the regimen consisted of cisplatin and 5-fluoro-deoxyuridine as continuous infusion. He developed some transient mental status changes and then left eye blindness. Ophthalmologic examination was compatible with retrobulbar neuritis. A brief review of reported cases of ophthalmologic toxicity in association with cisplatin is presented, and the likelihood that the toxicity is due to the drug itself rather than the method of administration is discussed.

show abstract

Local neurotoxicity of Cisplatin after intra-arterial chemotherapy

Cited by 11 publications

References 3 publications

The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice

The Clinical Impact of Vascular Endothelial Growth Factor/Receptor (VEGF/R) Inhibitors on Voice

Neurological complications of chemotherapy to the peripheral nervous system

Retrobulbar neuritis in a patient treated with intraarterial cisplatin for head and neck cancer

Contact Info

Product

Resources

About